Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia—a nuclear magnetic resonance study
Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia. Twenty-fo...
Saved in:
| Published in | International journal of cardiology Vol. 101; no. 3; pp. 441 - 447 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Shannon
Elsevier Ireland Ltd
08.06.2005
Elsevier Science |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0167-5273 1874-1754 |
| DOI | 10.1016/j.ijcard.2004.03.071 |
Cover
| Abstract | Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia.
Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined.
Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm,
p=0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm (
p=0.026). None of inflammation makers showed significant change by bezafibrate.
Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects. |
|---|---|
| AbstractList | Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia.BACKGROUNDHypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia.Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined.METHODSTwenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined.Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, p = 0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm (p = 0.026). None of inflammation makers showed significant change by bezafibrate.RESULTSBezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, p = 0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm (p = 0.026). None of inflammation makers showed significant change by bezafibrate.Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects.CONCLUSIONSBezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects. Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia. Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined. Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, p = 0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm (p = 0.026). None of inflammation makers showed significant change by bezafibrate. Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects. Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia. Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined. Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, p=0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm ( p=0.026). None of inflammation makers showed significant change by bezafibrate. Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects. |
| Author | Tohyama, Jun-ichiro Kido, Toshimi Mochizuki, Seibu Noma, Kenji Ikewaki, Katsunori |
| Author_xml | – sequence: 1 givenname: Katsunori surname: Ikewaki fullname: Ikewaki, Katsunori email: kikewaki@jikei.ac.jp – sequence: 2 givenname: Kenji surname: Noma fullname: Noma, Kenji – sequence: 3 givenname: Jun-ichiro surname: Tohyama fullname: Tohyama, Jun-ichiro – sequence: 4 givenname: Toshimi surname: Kido fullname: Kido, Toshimi – sequence: 5 givenname: Seibu surname: Mochizuki fullname: Mochizuki, Seibu |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16811012$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15907413$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1u1DAUhS1URKeFN0DIG9jNYCfOJEEICVXlR6rEBtbWjX3deurYg-2AwqoP0Sfsk-DRDCB1QVeRnO8c6dzvhBz54JGQ55ytOOPr15uV3SiIelUxJlasXrGWPyIL3rViydtGHJFFwdplU7X1MTlJacMK2PfdE3LMm561gtcLcntuDKqcaDB0wF9g7BAhIw2eOrsN2xgyWk_TNCgHKWGi4DW13jgYR8ghznSEeI0xlUe6hWzRl7afNl_Rq3mLMUd76WaF0WocLdzd3AL1k3IIsSQvPWaraMQUPHiFNOVJz0_JYwMu4bPD95R8-3D-9ezT8uLLx89n7y-WSog6L5u-G3QHulMtMGgEM1wp3nWCD4MRZqjFutG97quuahgOoFT5h3VTadCNXrP6lLza95aZ3ydMWY42KXQOPIYpyXXbibZvduCLAzgNI2q5jbasnuWfOxbg5QGApMCZWMbY9I9bd7xIqwr3Zs-pGFKKaKSyuRwt-BzBOsmZ3MmVG7mXK3dyJatlkVvC4l74b___Y-_2MSyn_GExyqSKJYXaxqJe6mAfKnh7r0A5623ZeY3zw_HfNePZzA |
| CODEN | IJCDD5 |
| CitedBy_id | crossref_primary_10_1111_j_1742_7843_2011_00675_x crossref_primary_10_3390_ijms232113499 crossref_primary_10_1185_030079907X187892 crossref_primary_10_1186_1476_511X_8_26 crossref_primary_10_5650_oleoscience_5_405 crossref_primary_10_1093_qjmed_hci154 crossref_primary_10_1124_pr_58_3_1 crossref_primary_10_1517_14712598_7_1_53 crossref_primary_10_5551_jat_11_278 crossref_primary_10_1002_cjoc_200990072 crossref_primary_10_1089_jmf_2014_0021 crossref_primary_10_5551_jat_27425 crossref_primary_10_5551_jat_ED007 crossref_primary_10_1016_j_amjcard_2013_08_033 crossref_primary_10_1186_1475_2840_11_140 crossref_primary_10_1016_j_atherosclerosis_2006_11_035 crossref_primary_10_1507_endocrj_K07E_065 crossref_primary_10_1016_j_vibspec_2012_01_001 crossref_primary_10_1186_1472_6904_8_10 crossref_primary_10_5551_jat_E563 crossref_primary_10_1007_s10557_013_6477_6 crossref_primary_10_1093_eurheartj_sul041 crossref_primary_10_1097_rmr_0b013e31815a0e5d |
| Cites_doi | 10.1093/clinchem/44.12.2490 10.1016/S0735-1097(98)00442-2 10.1161/01.ATV.18.7.1046 10.1038/31701 10.1093/clinchem/37.3.377 10.1016/S0002-9149(03)00165-6 10.1023/A:1007734924101 10.1093/clinchem/44.6.1242 10.1161/01.CIR.102.1.21 10.1016/S0011-393X(00)80010-7 10.1001/jama.1988.03410130125037 10.1093/clinchem/45.12.2136 10.1093/clinchem/41.5.717 10.1093/clinchem/47.5.893 10.1016/0021-9150(94)90124-4 10.1093/clinchem/32.6.957 10.1093/clinchem/38.9.1632 10.1161/01.ATV.20.11.2428 10.1161/01.CIR.0000033222.75187.B9 10.1161/01.CIR.95.1.69 10.1161/01.ATV.0000022015.97341.3A 10.1016/S0002-9343(01)01123-8 10.1056/NEJM199901143400207 10.1016/S0021-9150(01)00708-0 10.1093/clinchem/40.1.11 10.1056/NEJM199908053410604 |
| ContentType | Journal Article |
| Copyright | 2004 Elsevier Ireland Ltd 2005 INIST-CNRS |
| Copyright_xml | – notice: 2004 Elsevier Ireland Ltd – notice: 2005 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ijcard.2004.03.071 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1874-1754 |
| EndPage | 447 |
| ExternalDocumentID | 15907413 16811012 10_1016_j_ijcard_2004_03_071 S0167527304004267 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W KOM M29 M41 MO0 N9A O-L O9- OA. OAUVE OL~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UV1 WUQ X7M Z5R ZGI ~G- 0SF AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW EFLBG LCYCR NCXOZ RIG ZA5 AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c443t-598bd8ad8c7a0a540f1cc18841bbf4fb3465d9d928250ebacc884e352dad5d603 |
| IEDL.DBID | .~1 |
| ISSN | 0167-5273 |
| IngestDate | Fri Sep 05 14:18:13 EDT 2025 Wed Feb 19 01:40:24 EST 2025 Mon Jul 21 09:13:55 EDT 2025 Thu Apr 24 22:56:10 EDT 2025 Tue Jul 01 02:32:46 EDT 2025 Fri Feb 23 02:27:24 EST 2024 Tue Aug 26 16:56:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Inflammatory marker Lipoprotein Nuclear magnetic resonance Bezafibrate Triglyceride Human Biological marker Metabolic diseases Lipids Hyperlipoproteinemia Inflammation Enzymopathy Phlebology Hypertriglyceridemia Circulatory system Dyslipemia Cardiology |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c443t-598bd8ad8c7a0a540f1cc18841bbf4fb3465d9d928250ebacc884e352dad5d603 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 15907413 |
| PQID | 67847950 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_67847950 pubmed_primary_15907413 pascalfrancis_primary_16811012 crossref_citationtrail_10_1016_j_ijcard_2004_03_071 crossref_primary_10_1016_j_ijcard_2004_03_071 elsevier_sciencedirect_doi_10_1016_j_ijcard_2004_03_071 elsevier_clinicalkey_doi_10_1016_j_ijcard_2004_03_071 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2005-06-08 |
| PublicationDateYYYYMMDD | 2005-06-08 |
| PublicationDate_xml | – month: 06 year: 2005 text: 2005-06-08 day: 08 |
| PublicationDecade | 2000 |
| PublicationPlace | Shannon |
| PublicationPlace_xml | – name: Shannon – name: Netherlands |
| PublicationTitle | International journal of cardiology |
| PublicationTitleAlternate | Int J Cardiol |
| PublicationYear | 2005 |
| Publisher | Elsevier Ireland Ltd Elsevier Science |
| Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier Science |
| References | Ruotolo, Ericsson, Tettamanti (bib3) 1998; 32 Gomez-Gerique, Ros, Olivan (bib26) 2002; 162 Rubins, Robins, Collins (bib18) 1999; 341 Miida, Sakai, Ozaki (bib21) 2000; 20 Freedman, Otvos, Jeyarajah (bib8) 1998; 18 Hirano, Kazumi, Yoshino (bib4) 2000; 61 Rifai, Tracy, Ridker (bib16) 1999; 45 Otvos, Jeyarajah, Bennett, Krauss (bib7) 1992; 38 Rifai, Iannotti, DeAngelis, Law (bib12) 1998; 44 Ross (bib23) 1999; 340 Staels, Koenig, Habib (bib25) 1998; 393 Austin, Breslow, Hennekens (bib19) 1988; 260 (bib2) 2000; 102 Lundman, Eriksson, Silveira (bib24) 2003; 91 Lamarche, Tchernof, Moorjani (bib1) 1997; 95 Blake, Otvos, Rifai, Ridker (bib9) 2002; 106 Kondo, Muranaka, Ohta (bib15) 2001; 47 Jonkers, Mohrschladt, Westendorp, van der Laarse, Smelt (bib27) 2002; 112 Otvos, Jeyarajah, Bennett (bib5) 1991; 37 Sugiuchi, Uji, Okabe (bib11) 1995; 41 Kuller, Arnold, Tracy (bib10) 2002; 22 Rifai, King (bib13) 1986; 32 Leary, Wang, Baker (bib14) 1998; 44 Kataoka, Paidi, Howard (bib17) 1994; 40 La Ville, Sola, Motta (bib22) 1997; 11 Otvos (bib6) 2002; 48 Homma, Ozawa, Kobayashi (bib20) 1994; 106 Lamarche (10.1016/j.ijcard.2004.03.071_bib1) 1997; 95 Otvos (10.1016/j.ijcard.2004.03.071_bib7) 1992; 38 Lundman (10.1016/j.ijcard.2004.03.071_bib24) 2003; 91 Hirano (10.1016/j.ijcard.2004.03.071_bib4) 2000; 61 Kuller (10.1016/j.ijcard.2004.03.071_bib10) 2002; 22 Jonkers (10.1016/j.ijcard.2004.03.071_bib27) 2002; 112 Gomez-Gerique (10.1016/j.ijcard.2004.03.071_bib26) 2002; 162 Staels (10.1016/j.ijcard.2004.03.071_bib25) 1998; 393 Miida (10.1016/j.ijcard.2004.03.071_bib21) 2000; 20 Leary (10.1016/j.ijcard.2004.03.071_bib14) 1998; 44 Rifai (10.1016/j.ijcard.2004.03.071_bib16) 1999; 45 Ruotolo (10.1016/j.ijcard.2004.03.071_bib3) 1998; 32 La Ville (10.1016/j.ijcard.2004.03.071_bib22) 1997; 11 Rifai (10.1016/j.ijcard.2004.03.071_bib12) 1998; 44 Homma (10.1016/j.ijcard.2004.03.071_bib20) 1994; 106 Freedman (10.1016/j.ijcard.2004.03.071_bib8) 1998; 18 Rubins (10.1016/j.ijcard.2004.03.071_bib18) 1999; 341 Rifai (10.1016/j.ijcard.2004.03.071_bib13) 1986; 32 Kondo (10.1016/j.ijcard.2004.03.071_bib15) 2001; 47 Blake (10.1016/j.ijcard.2004.03.071_bib9) 2002; 106 (10.1016/j.ijcard.2004.03.071_bib2) 2000; 102 Otvos (10.1016/j.ijcard.2004.03.071_bib5) 1991; 37 Austin (10.1016/j.ijcard.2004.03.071_bib19) 1988; 260 Otvos (10.1016/j.ijcard.2004.03.071_bib6) 2002; 48 Kataoka (10.1016/j.ijcard.2004.03.071_bib17) 1994; 40 Sugiuchi (10.1016/j.ijcard.2004.03.071_bib11) 1995; 41 Ross (10.1016/j.ijcard.2004.03.071_bib23) 1999; 340 |
| References_xml | – volume: 260 start-page: 1917 year: 1988 end-page: 1921 ident: bib19 article-title: Low-density lipoprotein subclass patterns and risk of myocardial infarction publication-title: JAMA – volume: 61 start-page: 127 year: 2000 end-page: 136 ident: bib4 article-title: Long-term efficacy of bezafbrate in reductionof small, dense low-density lipoprotein by hypotriglyceridemic action publication-title: Curr. Ther. Res. Clin. Exp. – volume: 37 start-page: 377 year: 1991 end-page: 386 ident: bib5 article-title: Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy publication-title: Clin. Chem. – volume: 106 start-page: 1930 year: 2002 end-page: 1937 ident: bib9 article-title: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women publication-title: Circulation – volume: 22 start-page: 1175 year: 2002 end-page: 1180 ident: bib10 article-title: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 40 start-page: 11 year: 1994 end-page: 13 ident: bib17 article-title: Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype publication-title: Clin. Chem. – volume: 32 start-page: 957 year: 1986 end-page: 961 ident: bib13 article-title: Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum publication-title: Clin. Chem. – volume: 18 start-page: 1046 year: 1998 end-page: 1053 ident: bib8 article-title: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 41 start-page: 717 year: 1995 end-page: 723 ident: bib11 article-title: Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin publication-title: Clin. Chem. – volume: 44 start-page: 2490 year: 1998 end-page: 24908 ident: bib14 article-title: Evaluation of an immunoseparation method for quantitative measurement of remanant-like particle-cholesterol in serum and plasma publication-title: Clin. Chem. – volume: 48 start-page: 171 year: 2002 end-page: 180 ident: bib6 article-title: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy publication-title: Clin. Lab. – volume: 20 start-page: 2428 year: 2000 end-page: 2433 ident: bib21 article-title: Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 11 start-page: 653 year: 1997 end-page: 658 ident: bib22 article-title: Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts publication-title: Cardiovasc. Drugs Ther. – volume: 32 start-page: 1648 year: 1998 end-page: 1656 ident: bib3 article-title: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) publication-title: J. Am. Coll. Cardiol. – volume: 45 start-page: 2136 year: 1999 end-page: 2141 ident: bib16 article-title: Clinical efficacy of an automated high-sensitivity C-reactive protein assay publication-title: Clin. Chem. – volume: 340 start-page: 115 year: 1999 end-page: 126 ident: bib23 article-title: Atherosclerosis—an inflammatory disease publication-title: N. Engl. J Med. – volume: 112 start-page: 275 year: 2002 end-page: 280 ident: bib27 article-title: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial publication-title: Am. J. Med. – volume: 95 start-page: 69 year: 1997 end-page: 75 ident: bib1 article-title: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study publication-title: Circulation – volume: 106 start-page: 191 year: 1994 end-page: 201 ident: bib20 article-title: Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia publication-title: Atherosclerosis – volume: 341 start-page: 410 year: 1999 end-page: 418 ident: bib18 article-title: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group publication-title: New Engl. J. Med. – volume: 102 start-page: 21 year: 2000 end-page: 27 ident: bib2 article-title: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study publication-title: Circulation – volume: 91 start-page: 1128 year: 2003 end-page: 1131 ident: bib24 article-title: Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1) publication-title: Am. J. Cardiol. – volume: 38 start-page: 1632 year: 1992 end-page: 1638 ident: bib7 article-title: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement publication-title: Clin. Chem. – volume: 47 start-page: 893 year: 2001 end-page: 900 ident: bib15 article-title: Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL publication-title: Clin. Chem. – volume: 44 start-page: 1242 year: 1998 end-page: 1250 ident: bib12 article-title: Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg publication-title: Clin. Chem. – volume: 162 start-page: 245 year: 2002 end-page: 251 ident: bib26 article-title: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia publication-title: Atherosclerosis – volume: 393 start-page: 790 year: 1998 end-page: 793 ident: bib25 article-title: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators publication-title: Nature – volume: 44 start-page: 2490 year: 1998 ident: 10.1016/j.ijcard.2004.03.071_bib14 article-title: Evaluation of an immunoseparation method for quantitative measurement of remanant-like particle-cholesterol in serum and plasma publication-title: Clin. Chem. doi: 10.1093/clinchem/44.12.2490 – volume: 32 start-page: 1648 year: 1998 ident: 10.1016/j.ijcard.2004.03.071_bib3 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/S0735-1097(98)00442-2 – volume: 48 start-page: 171 year: 2002 ident: 10.1016/j.ijcard.2004.03.071_bib6 article-title: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy publication-title: Clin. Lab. – volume: 18 start-page: 1046 year: 1998 ident: 10.1016/j.ijcard.2004.03.071_bib8 article-title: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.18.7.1046 – volume: 393 start-page: 790 year: 1998 ident: 10.1016/j.ijcard.2004.03.071_bib25 article-title: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators publication-title: Nature doi: 10.1038/31701 – volume: 37 start-page: 377 year: 1991 ident: 10.1016/j.ijcard.2004.03.071_bib5 article-title: Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy publication-title: Clin. Chem. doi: 10.1093/clinchem/37.3.377 – volume: 91 start-page: 1128 year: 2003 ident: 10.1016/j.ijcard.2004.03.071_bib24 article-title: Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1) publication-title: Am. J. Cardiol. doi: 10.1016/S0002-9149(03)00165-6 – volume: 11 start-page: 653 year: 1997 ident: 10.1016/j.ijcard.2004.03.071_bib22 article-title: Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts publication-title: Cardiovasc. Drugs Ther. doi: 10.1023/A:1007734924101 – volume: 44 start-page: 1242 year: 1998 ident: 10.1016/j.ijcard.2004.03.071_bib12 article-title: Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method publication-title: Clin. Chem. doi: 10.1093/clinchem/44.6.1242 – volume: 102 start-page: 21 year: 2000 ident: 10.1016/j.ijcard.2004.03.071_bib2 article-title: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study publication-title: Circulation doi: 10.1161/01.CIR.102.1.21 – volume: 61 start-page: 127 year: 2000 ident: 10.1016/j.ijcard.2004.03.071_bib4 article-title: Long-term efficacy of bezafbrate in reductionof small, dense low-density lipoprotein by hypotriglyceridemic action publication-title: Curr. Ther. Res. Clin. Exp. doi: 10.1016/S0011-393X(00)80010-7 – volume: 260 start-page: 1917 year: 1988 ident: 10.1016/j.ijcard.2004.03.071_bib19 article-title: Low-density lipoprotein subclass patterns and risk of myocardial infarction publication-title: JAMA doi: 10.1001/jama.1988.03410130125037 – volume: 45 start-page: 2136 year: 1999 ident: 10.1016/j.ijcard.2004.03.071_bib16 article-title: Clinical efficacy of an automated high-sensitivity C-reactive protein assay publication-title: Clin. Chem. doi: 10.1093/clinchem/45.12.2136 – volume: 41 start-page: 717 year: 1995 ident: 10.1016/j.ijcard.2004.03.071_bib11 article-title: Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin publication-title: Clin. Chem. doi: 10.1093/clinchem/41.5.717 – volume: 47 start-page: 893 year: 2001 ident: 10.1016/j.ijcard.2004.03.071_bib15 article-title: Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL publication-title: Clin. Chem. doi: 10.1093/clinchem/47.5.893 – volume: 106 start-page: 191 year: 1994 ident: 10.1016/j.ijcard.2004.03.071_bib20 article-title: Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia publication-title: Atherosclerosis doi: 10.1016/0021-9150(94)90124-4 – volume: 32 start-page: 957 year: 1986 ident: 10.1016/j.ijcard.2004.03.071_bib13 article-title: Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum publication-title: Clin. Chem. doi: 10.1093/clinchem/32.6.957 – volume: 38 start-page: 1632 year: 1992 ident: 10.1016/j.ijcard.2004.03.071_bib7 article-title: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement publication-title: Clin. Chem. doi: 10.1093/clinchem/38.9.1632 – volume: 20 start-page: 2428 year: 2000 ident: 10.1016/j.ijcard.2004.03.071_bib21 article-title: Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.20.11.2428 – volume: 106 start-page: 1930 year: 2002 ident: 10.1016/j.ijcard.2004.03.071_bib9 article-title: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women publication-title: Circulation doi: 10.1161/01.CIR.0000033222.75187.B9 – volume: 95 start-page: 69 year: 1997 ident: 10.1016/j.ijcard.2004.03.071_bib1 article-title: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study publication-title: Circulation doi: 10.1161/01.CIR.95.1.69 – volume: 22 start-page: 1175 year: 2002 ident: 10.1016/j.ijcard.2004.03.071_bib10 article-title: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.0000022015.97341.3A – volume: 112 start-page: 275 year: 2002 ident: 10.1016/j.ijcard.2004.03.071_bib27 article-title: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial publication-title: Am. J. Med. doi: 10.1016/S0002-9343(01)01123-8 – volume: 340 start-page: 115 year: 1999 ident: 10.1016/j.ijcard.2004.03.071_bib23 article-title: Atherosclerosis—an inflammatory disease publication-title: N. Engl. J Med. doi: 10.1056/NEJM199901143400207 – volume: 162 start-page: 245 year: 2002 ident: 10.1016/j.ijcard.2004.03.071_bib26 article-title: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia publication-title: Atherosclerosis doi: 10.1016/S0021-9150(01)00708-0 – volume: 40 start-page: 11 year: 1994 ident: 10.1016/j.ijcard.2004.03.071_bib17 article-title: Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype publication-title: Clin. Chem. doi: 10.1093/clinchem/40.1.11 – volume: 341 start-page: 410 year: 1999 ident: 10.1016/j.ijcard.2004.03.071_bib18 article-title: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group publication-title: New Engl. J. Med. doi: 10.1056/NEJM199908053410604 |
| SSID | ssj0004998 |
| Score | 1.9018775 |
| Snippet | Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 441 |
| SubjectTerms | Bezafibrate Bezafibrate - therapeutic use Biological and medical sciences Body Mass Index C-Reactive Protein - metabolism Cardiology. Vascular system Chemokine CCL2 - blood Cholesterol, HDL - blood Cholesterol, VLDL - blood Disorders of blood lipids. Hyperlipoproteinemia Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Humans Hypertriglyceridemia - blood Hypertriglyceridemia - diagnosis Hypertriglyceridemia - drug therapy Hypolipidemic Agents - therapeutic use Inflammation - blood Inflammatory marker Interleukin-6 - blood Lipoprotein Lipoproteins - blood Lipoproteins, HDL - blood Lipoproteins, HDL3 Lipoproteins, LDL - blood Magnetic Resonance Spectroscopy Male Medical sciences Metabolic diseases Middle Aged Nephelometry and Turbidimetry Nuclear magnetic resonance Risk Factors Triglyceride Triglycerides - blood |
| Title | Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia—a nuclear magnetic resonance study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0167527304004267 https://dx.doi.org/10.1016/j.ijcard.2004.03.071 https://www.ncbi.nlm.nih.gov/pubmed/15907413 https://www.proquest.com/docview/67847950 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier Science Direct Complete Freedom Collection customDbUrl: eissn: 1874-1754 dateEnd: 20151215 omitProxy: true ssIdentifier: ssj0004998 issn: 0167-5273 databaseCode: ACRLP dateStart: 19950127 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1874-1754 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004998 issn: 0167-5273 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1874-1754 dateEnd: 20151215 omitProxy: true ssIdentifier: ssj0004998 issn: 0167-5273 databaseCode: AIKHN dateStart: 19950127 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1874-1754 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004998 issn: 0167-5273 databaseCode: AKRWK dateStart: 19810101 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhhVAopU1f28dWh17dtdeyLR9DaNimJJc2kJsZvVqHjbysvYf2UPoj8gv7Szoj21lyCCm5yh4Qmk-jGWnmG8Y-QKlyC7GL5jKGSKRQRCCUjHLj6BEICiWoOPnkNF-ciePz7HyHHY61MJRWOdj-3qYHaz2MzIbVnK3qevaVEuiJPizAcJ5TRTmxfyGmP_7epnmgRy9Hfm_6eyyfCzle9YVGPYQoMVCdFsltx9OjFbS4aK7vdnG7OxqOpaMn7PHgT_KDfspP2Y71-2zvZHgxf8auenriljeOK_sLHIXHneWN58t61QSahtrzdqM0-dG25eANR9ghUi7DCzy_pAyedYuDfGBhbTld3_IfGMOuOwzvlz81Apny7OHvnyvgnkiSYY2S3z0VSXKM6Rti9rA80Nk-Z2dHn74dLqKhE0OkhUi7KCulMhKM1AXEgE6eS7ROpBSJUk44leK6m9KUVAgbWwVa4zeLvp0Bk5k8Tl-wXd94-4rxuExdbqyAMgHhMoMSGFGWBkQ-L7TTE5aOCqj0QFNO3TKW1ZiPdlH1aqMOmqKK0wrVNmHRtdSqp-m44_9s1G01lqCi0azwHLlDrriWuwHT_5Cc3oDQdpq5TIhkbcLej5iqcIvTuw1422zaCv0JUZRZPGEve6htZTO620jS1_ee1hv2MJDR0r2SfMt2u_XGvkM3q1PTsI-m7MHB5y-L03_MBCy5 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBa6FNgGDMNe3bJHq8OuRuxYfh2LYkW6NrmsBXoTqNfmIrWD2Dlsp_2I_sL9kpGy3aCHosOusj9AECmKlMiPjH2GQqUWQhdM8xACEUMWgFB5kBpHj0CQKUHFyfNFOrsQXy-Tyx12NNTCUFplb_s7m-6tdT8y6VdzsirLyTdKoCf6MK-G0zR7xHZFgjZ5xHYPT05ni215ZOFb4nqKbwIMFXQ-zau80igKHyh6ttMsuu-EeraCBtfNdQ0v7vdI_cl0_II9711KftjN-iXbsdUr9njeP5q_ZjcdQ3HDa8eV_QWOIuTW8rriy3JVe6aGsuLNRmlypW3DoTIcNQ-V5do_wvNrSuJZNzjIeyLWhtMNLv-BYey6xQh_-VOjLlOqPfz5fQO8Ip5kWCPye0V1khzD-prIPSz3jLZv2MXxl_OjWdA3Ywi0EHEbJEWuTA4m1xmEgH6ei7SO8lxESjnhVCzSxBSmoFrY0CrQGr9ZdO8MmMSkYbzHRlVd2XeMh0XsUmMFFBEIlxhEYFBZGBDpNNNOj1k8CEDqnqmcGmYs5ZCSdiU7sVETTSHDWKLYxiy4Ra06po4H_k8G2cqhChXtpsSj5AFcdou7o6n_gNy_o0LbaaZ5RDxrY3Yw6JTEXU5PN1DZetNIdClEViThmL3tVG2LTeh6I4rf__e0DtiT2fn8TJ6dLE4_sKeem5aumfKPbNSuN_YTel2t2u931V_fbS9k |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+bezafibrate+on+lipoprotein+subclasses+and+inflammatory+markers+in+patients+with+hypertriglyceridemia+%3A+a+nuclear+magnetic+resonance+study&rft.jtitle=International+journal+of+cardiology&rft.au=IKEWAKI%2C+Katsunori&rft.au=NOMA%2C+Kenji&rft.au=TOHYAMA%2C+Jun-Ichiro&rft.au=KIDO%2C+Toshimi&rft.date=2005-06-08&rft.pub=Elsevier+Science&rft.issn=0167-5273&rft.volume=101&rft.issue=3&rft.spage=441&rft.epage=447&rft_id=info:doi/10.1016%2Fj.ijcard.2004.03.071&rft.externalDBID=n%2Fa&rft.externalDocID=16811012 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-5273&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-5273&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-5273&client=summon |